Merck & Company Inc (MRK)vsNovo Nordisk A/S (NVO)
MRK
Merck & Company Inc
$146.78
-0.19%
HEALTHCARE · Cap: $355.10B
NVO
Novo Nordisk A/S
$43.24
+0.12%
HEALTHCARE · Cap: $205.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 395% more annual revenue ($329.43B vs $66.57B). NVO leads profitability with a 35.3% profit margin vs 4.8%. MRK appears more attractively valued with a PEG of 2.64. NVO earns a higher WallStSmart Score of 58/100 (C).
MRK
Hold36
out of 100
Grade: F
NVO
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$146.78
$63.74 premium
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 42.5%
Generating 42.4B in free cash flow
Areas to Watch
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
2.1% revenue growth
Weak financial health signals
Expensive relative to growth rate
Earnings declined 20.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 35.3% and operating margin at 42.5%.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : NVO
The primary concerns for NVO are Revenue Growth, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
NVO carries more volatility with a beta of 0.34 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
NVO generates stronger free cash flow (42.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVO scores higher overall (58/100 vs 36/100), backed by strong 35.3% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?